150 related articles for article (PubMed ID: 15131061)
1. Antisense RNA down-regulation of bcl-2 expression in DU145 prostate cancer cells does not diminish the cytostatic effects of G3139 (Oblimersen).
Raffo A; Lai JC; Stein CA; Miller P; Scaringe S; Khvorova A; Benimetskaya L
Clin Cancer Res; 2004 May; 10(9):3195-206. PubMed ID: 15131061
[TBL] [Abstract][Full Text] [Related]
2. Relative Bcl-2 independence of drug-induced cytotoxicity and resistance in 518A2 melanoma cells.
Benimetskaya L; Lai JC; Khvorova A; Wu S; Hua E; Miller P; Zhang LM; Stein CA
Clin Cancer Res; 2004 Dec; 10(24):8371-9. PubMed ID: 15623615
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of potentially anti-apoptotic proteins by antisense protein kinase C-alpha (Isis 3521) and antisense bcl-2 (G3139) phosphorothioate oligodeoxynucleotides: relationship to the decreased viability of T24 bladder and PC3 prostate cancer cells.
Benimetskaya L; Miller P; Benimetsky S; Maciaszek A; Guga P; Beaucage SL; Wilk A; Grajkowski A; Halperin AL; Stein CA
Mol Pharmacol; 2001 Dec; 60(6):1296-307. PubMed ID: 11723237
[TBL] [Abstract][Full Text] [Related]
4. Changes in gene expression induced by phosphorothioate oligodeoxynucleotides (including G3139) in PC3 prostate carcinoma cells are recapitulated at least in part by treatment with interferon-beta and -gamma.
Benimetskaya L; Wittenberger T; Stein CA; Hofmann HP; Weller C; Lai JC; Miller P; Gekeler V
Clin Cancer Res; 2004 Jun; 10(11):3678-88. PubMed ID: 15173074
[TBL] [Abstract][Full Text] [Related]
5. G3139 (oblimersen) may inhibit prostate cancer cell growth in a partially bis-CpG-dependent non-antisense manner.
Lai JC; Benimetskaya L; Santella RM; Wang Q; Miller PS; Stein CA
Mol Cancer Ther; 2003 Oct; 2(10):1031-43. PubMed ID: 14578468
[TBL] [Abstract][Full Text] [Related]
6. Bcl-2 protein in 518A2 melanoma cells in vivo and in vitro.
Benimetskaya L; Ayyanar K; Kornblum N; Castanotto D; Rossi J; Wu S; Lai J; Brown BD; Popova N; Miller P; McMicken H; Chen Y; Stein CA
Clin Cancer Res; 2006 Aug; 12(16):4940-8. PubMed ID: 16914583
[TBL] [Abstract][Full Text] [Related]
7. Antisense RNA down-regulation of bcl-xL Expression in prostate cancer cells leads to diminished rates of cellular proliferation and resistance to cytotoxic chemotherapeutic agents.
Vilenchik M; Raffo AJ; Benimetskaya L; Shames D; Stein CA
Cancer Res; 2002 Apr; 62(7):2175-83. PubMed ID: 11929841
[TBL] [Abstract][Full Text] [Related]
8. Gene profiling study of G3139- and Bcl-2-targeting siRNAs identifies a unique G3139 molecular signature.
Anderson EM; Miller P; Ilsley D; Marshall W; Khvorova A; Stein CA; Benimetskaya L
Cancer Gene Ther; 2006 Apr; 13(4):406-14. PubMed ID: 16195754
[TBL] [Abstract][Full Text] [Related]
9. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis.
Frankel SR
Semin Oncol; 2003 Apr; 30(2):300-4. PubMed ID: 12720157
[TBL] [Abstract][Full Text] [Related]
10. G3139 induces cell death by caspase-dependent and -independent apoptosis on human melanoma cell lines.
Nakamura S; Inui M; Kamei T; Nakase M; Okumura K; Tagawa T
Oncol Rep; 2006 Jun; 15(6):1563-8. PubMed ID: 16685396
[TBL] [Abstract][Full Text] [Related]
11. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
Loomis R; Carbone R; Reiss M; Lacy J
Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
[TBL] [Abstract][Full Text] [Related]
12. A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
Tolcher AW; Kuhn J; Schwartz G; Patnaik A; Hammond LA; Thompson I; Fingert H; Bushnell D; Malik S; Kreisberg J; Izbicka E; Smetzer L; Rowinsky EK
Clin Cancer Res; 2004 Aug; 10(15):5048-57. PubMed ID: 15297406
[TBL] [Abstract][Full Text] [Related]
13. Cellular uptake and intracellular levels of the bcl-2 antisense g3139 in cultured cells and treated patients with acute myeloid leukemia.
Dai G; Chan KK; Liu S; Hoyt D; Whitman S; Klisovic M; Shen T; Caligiuri MA; Byrd J; Grever M; Marcucci G
Clin Cancer Res; 2005 Apr; 11(8):2998-3008. PubMed ID: 15837754
[TBL] [Abstract][Full Text] [Related]
14. Phosphorothioate oligodeoxynucleotides and G3139 induce apoptosis in 518A2 melanoma cells.
Lai JC; Benimetskaya L; Khvorova A; Wu S; Hua E; Miller P; Stein CA
Mol Cancer Ther; 2005 Feb; 4(2):305-15. PubMed ID: 15713901
[TBL] [Abstract][Full Text] [Related]
15. Electroporation increases antitumoral efficacy of the bcl-2 antisense G3139 and chemotherapy in a human melanoma xenograft.
Spugnini EP; Biroccio A; De Mori R; Scarsella M; D'Angelo C; Baldi A; Leonetti C
J Transl Med; 2011 Jul; 9():125. PubMed ID: 21798045
[TBL] [Abstract][Full Text] [Related]
16. Why G3139 works poorly in cancer trials but might work well against HIV.
Parris GE
Med Hypotheses; 2007; 69(3):537-40. PubMed ID: 17363184
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Bcl-2 enhances the efficacy of epirubicin chemotherapy in PC-3 prostate cancer cells.
Jiang H; Xia D; Wu LJ; Chen ZD
Chin Med J (Engl); 2011 Dec; 124(23):4018-21. PubMed ID: 22340335
[TBL] [Abstract][Full Text] [Related]
18. Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity.
Lebedeva I; Rando R; Ojwang J; Cossum P; Stein CA
Cancer Res; 2000 Nov; 60(21):6052-60. PubMed ID: 11085527
[TBL] [Abstract][Full Text] [Related]
19. Induction of apoptosis by G3139 in melanoma cells.
Benimetskaya L; Lai JC; Khvorova A; Wu S; Miller P; Stein CA
Ann N Y Acad Sci; 2005 Nov; 1058():235-45. PubMed ID: 16394140
[TBL] [Abstract][Full Text] [Related]
20. Bcl-2 antisense in the treatment of human malignancies: a delusion in targeted therapy.
Gjertsen BT; Bredholt T; Anensen N; Vintermyr OK
Curr Pharm Biotechnol; 2007 Dec; 8(6):373-81. PubMed ID: 18289046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
